114 related articles for article (PubMed ID: 7670136)
21. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Vrana JA; Saunders AM; Chellappan SP; Grant S
Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
[TBL] [Abstract][Full Text] [Related]
22. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
23. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.
Maki A; Mohammad R; Raza S; Saleh M; Govindaraju KD; Pettit GR; al-Katib A
Anticancer Drugs; 1996 May; 7(3):344-50. PubMed ID: 8792010
[TBL] [Abstract][Full Text] [Related]
24. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Reddy KB; Al-Katib AM
Int J Mol Med; 2000 Feb; 5(2):165-71. PubMed ID: 10639596
[TBL] [Abstract][Full Text] [Related]
25. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
Wall NR; Beck FW; Al-Katib AM; Mohammad RM
J Drug Target; 2001; 9(5):329-39. PubMed ID: 11770703
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
[TBL] [Abstract][Full Text] [Related]
27. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
[TBL] [Abstract][Full Text] [Related]
30. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
31. Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).
Wang Z; Wang S; Dai Y; Grant S
J Pharmacol Exp Ther; 2002 May; 301(2):568-77. PubMed ID: 11961058
[TBL] [Abstract][Full Text] [Related]
32. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
Vrana JA; Rao AS; Wang Z; Jarvis WD; Grant S
Int J Oncol; 1998 Apr; 12(4):927-34. PubMed ID: 9499457
[TBL] [Abstract][Full Text] [Related]
33. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
[TBL] [Abstract][Full Text] [Related]
34. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
35. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.
Nabha SM; Wall NR; Mohammad RM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2000 Jun; 11(5):385-92. PubMed ID: 10912955
[TBL] [Abstract][Full Text] [Related]
36. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
[TBL] [Abstract][Full Text] [Related]
37. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Wang S; Wang Z; Grant S
Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
[TBL] [Abstract][Full Text] [Related]
38. Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases.
Wang Y; Zhang J; Wang Q; Zhang T; Yang Y; Yi Y; Gao G; Dong H; Zhu H; Li Y; Lin H; Tang H; Chen X
Eur J Pharmacol; 2013 Oct; 718(1-3):340-9. PubMed ID: 24036350
[TBL] [Abstract][Full Text] [Related]
39. As2O3 induces apoptosis of the human B lymphoma cell line MBC-1.
Shen L; Chen TX; Wang YP; Lin Z; Zhao HJ; Zu YZ; Wu G; Ying DM
J Biol Regul Homeost Agents; 2000; 14(2):116-9. PubMed ID: 10841286
[TBL] [Abstract][Full Text] [Related]
40. Studies of apoptosis of malignant lymphoma cells induced by arsenic trioxide.
Zhang Y; Nie L
Cell Biol Int; 2001; 25(10):1003-6. PubMed ID: 11589617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]